Curaleaf Holdings (CURLF) Income from Non-Controlling Interests (2020 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Income from Non-Controlling Interests of -$16000.0 for Q1 2026, down 101.96% year-on-year from $817000.0 in Q1 2025, and up 96.4% on a QoQ basis from -$445000.0 in Q2 2025.
Curaleaf Holdings (CURLF) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Income from Non-Controlling Interests for 7 consecutive years, with -$16000.0 the latest figure, recorded in Q1 2026.
- Quarterly Income from Non-Controlling Interests fell 101.96% year-over-year to -$16000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.3 million (up 5.62% YoY) and the FY2025 annual result came in at $2.9 million, down 92.93% from the prior year.
- Income from Non-Controlling Interests advanced to -$16000.0 in Q1 2026 per CURLF's latest filing, from -$445000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for CURLF reached as high as $46.9 million in Q4 2024 and fell as low as -$2.7 billion in Q1 2024.
- A 5-year average of -$362.6 million and a median of -$230500.0 in 2025 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests soared 106.91% — and 2024, when it plunged 4494999999900.0%.
- Year by year, Income from Non-Controlling Interests stood at -$2.4 million in 2022, then plunged by 99941.36% to -$2.4 billion in 2023, then jumped by 101.94% to $46.9 million in 2024, then tumbled by 100.95% to -$445000.0 in 2025, then soared by 96.4% to -$16000.0 in 2026.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$16000.0, -$445000.0, and $817000.0 for Q1 2026, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.57 Bn | 30.63 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.08 Bn | 20.93 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.43 Bn | 22.43 Bn | - | - |
| 7 | Viatris | 20.23 Bn | 18.42 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | - |
| 10 | Curaleaf Holdings | 6.98 Bn | 6.98 Bn | 157.29 Mn | -16,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16,000.00 |
| Jun 30, 2025 | -445,000.00 |
| Mar 31, 2025 | 817,000.00 |
| Dec 31, 2024 | 46.94 Mn |
| Sep 30, 2024 | -2.03 Mn |
| Jun 30, 2024 | -945,000.00 |
| Mar 31, 2024 | -2.70 Bn |
| Dec 31, 2023 | -2.42 Bn |
| Sep 30, 2023 | -0.04 |
| Jun 30, 2023 | -0.01 |
| Mar 31, 2023 | -0.06 |
| Dec 31, 2022 | -2.42 Mn |
| Sep 30, 2022 | -2.77 Mn |
| Jun 30, 2022 | 127,000.00 |
| Dec 31, 2021 | -2.54 Mn |
| Sep 30, 2021 | -2.36 Mn |
| Jun 30, 2021 | -1.84 Mn |
| Mar 31, 2021 | 363.00 |
| Dec 31, 2020 | 165.00 |
| Jun 30, 2020 | 193.00 |